Revolution Medicines (RVMD) director sells 12,871 shares in 10b5-1 trade

Rhea-AI Filing Summary

Revolution Medicines director Mark A. Goldsmith sold 12,871 shares of common stock in an open-market transaction at an average price of $99.4804 per share on March 17, 2026. The sale was made under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations from vesting restricted stock units.

After the sale, he holds 276,698 shares directly, including 201,150 RSUs. He also has indirect holdings through trusts, with reported positions of 594,060, 64,424, and 64,424 shares of common stock held in separate revocable trusts.

Insights

Equity compensation and insider-trading analyst

Small pre-planned sale tied to RSU tax withholding looks routine.

The filing shows Mark A. Goldsmith executed an open-market sale of 12,871 Revolution Medicines shares at $99.4804 per share. A footnote states this was done under a Rule 10b5-1 instruction letter to cover tax withholding from RSU vesting, indicating a pre-planned, compensation-driven trade.

Following the transaction, he still directly owns 276,698 shares, including 201,150 RSUs, and holds additional indirect positions of 594,060, 64,424, and 64,424 shares through family trusts. Relative to these combined holdings, the sale size appears modest and consistent with routine liquidity needs linked to equity awards rather than a directional change in exposure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		12,871	D	$99.4804	276,698(2)	D
Common Stock								594,060	I	Trust(3)
Common Stock								64,424	I	Trust(4)
Common Stock								64,424	I	Trust(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 201,150 RSUs.

3. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

4. Held by Jonathan Goldsmith Revocable Trust.

5. Held by Rebecca Goldsmith Revocable Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RVMD director Mark A. Goldsmith report?

Mark A. Goldsmith reported selling 12,871 shares of Revolution Medicines common stock. The shares were sold in an open-market transaction at an average price of $99.4804 per share on March 17, 2026, according to the Form 4 filing.

Was the RVMD insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023. The plan was established to satisfy Goldsmith’s tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.

How many Revolution Medicines shares does Mark A. Goldsmith hold after the sale?

After the reported sale, Goldsmith directly holds 276,698 shares of Revolution Medicines common stock. This direct position includes 201,150 restricted stock units (RSUs) that are part of his equity compensation, as disclosed in the Form 4 footnotes.

What indirect RVMD shareholdings are reported for Mark A. Goldsmith?

The filing lists indirect holdings through trusts totaling three separate positions. These include 594,060 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, plus 64,424 shares in each of the Jonathan and Rebecca Goldsmith Revocable Trusts.

What is the purpose of the RVMD insider’s reported share sale?

The sale is described as satisfying tax withholding obligations tied to vesting restricted stock units. A Rule 10b5-1 instruction letter adopted in May 2023 governs these transactions, framing the activity as part of a pre-arranged plan rather than a discretionary market-timing decision.

What role does equity compensation play in Mark A. Goldsmith’s RVMD holdings?

Equity compensation is significant in Goldsmith’s stake, with 201,150 RSUs included in his direct holdings of 276,698 shares. RSUs vest over time and can create tax obligations, which this Form 4 indicates are partially addressed through pre-planned share sales.